Evidence map›Paper›PMID 35673349›Full record

ArticleClinical ophthalmology (Auckland, N.Z.)2022

Safety of Intravenous Methylprednisolone in Refractory and Severe Pediatric Uveitis.

Hashem H Ghoraba, Wataru Matsumiya, Hassan Khojasteh, Amir Akhavanrezayat, Irmak Karaca, Christopher Or, Negin Yavari, Sherin Lajevardi, Jaclyn Hwang, Cigdem Yasar and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical ophthalmology (Auckland, N.Z.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Safe Use of Corticosteroids in Non-Infectious Uveitis.Journal of inflammation research · 2025
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Hashem H GhorabaSpencer Center for Vision Research, Byers Eye Institute, Stanford University, Palo Alto, CA, USA.
Wataru MatsumiyaSpencer Center for Vision Research, Byers Eye Institute, Stanford University, Palo Alto, CA, USA.
Hassan KhojastehSpencer Center for Vision Research, Byers Eye Institute, Stanford University, Palo Alto, CA, USA.
Amir AkhavanrezayatSpencer Center for Vision Research, Byers Eye Institute, Stanford University, Palo Alto, CA, USA.
Irmak KaracaSpencer Center for Vision Research, Byers Eye Institute, Stanford University, Palo Alto, CA, USA.ORCID 0000-0001-7927-0887
Christopher OrSpencer Center for Vision Research, Byers Eye Institute, Stanford University, Palo Alto, CA, USA.
Negin YavariSpencer Center for Vision Research, Byers Eye Institute, Stanford University, Palo Alto, CA, USA.
Sherin LajevardiSpencer Center for Vision Research, Byers Eye Institute, Stanford University, Palo Alto, CA, USA.
Jaclyn HwangSpencer Center for Vision Research, Byers Eye Institute, Stanford University, Palo Alto, CA, USA.ORCID 0000-0001-7756-3918
Cigdem YasarSpencer Center for Vision Research, Byers Eye Institute, Stanford University, Palo Alto, CA, USA.ORCID 0000-0003-0386-3613
Diana DoSpencer Center for Vision Research, Byers Eye Institute, Stanford University, Palo Alto, CA, USA.
Quan Dong NguyenSpencer Center for Vision Research, Byers Eye Institute, Stanford University, Palo Alto, CA, USA.

Funding

Stanford Vision Research CoreP30EY026877 · NEI · STANFORD UNIVERSITY · PI Jeffrey L Goldberg · 2017 to 2026
$8.0M
NEI NIH HHS P30 EY026877
6 · The paper itself

Abstract

Purpose: To evaluate the safety of intravenous high-dose pulse methylprednisolone succinate (IVHDM) in the management of severe or refractory non-infectious pediatric uveitis. Methods: We reviewed all uveitis patients who were ≤16 years of age and who received IVHDM with a dose of ≥500 mg per day (1-3 days a month) for at least 3 months during their management at a tertiary care eye hospital. Results: Twenty pediatric patients with severe or refractory uveitis who received IVHDM were identified. Six patients received IVHDM either once, as a preoperative medication, or at a lower dose than 500 mg, and were excluded. The remaining 14 patients received IVHDM for at least 4 months. Age (mean±SD) was 11.9±2.4 years and 50% were female. Duration of treatment was 14.2±7.5 months. Thirteen patients received IVHDM in combination with other immunomodulatory therapy (IMT). Except for two outliers, IVHDM was given at a dose of 8-25 mg/kg per infusion. Three major adverse events (AEs) occurred in two patients: a single episode of bradycardia, compression fracture following minor trauma and adrenal insufficiency. The number of AEs (major and minor) strongly correlated with duration of treatment ( Conclusion: IVHDM may be a valid therapeutic option for aggressive/refractory pediatric uveitis. The reported AEs in this series can also be attributed to the concurrent IMT or the underlying disease itself.

Indexed as

adverse eventsintravenous methylprednisolonepediatric uveitis

Identifiers

PMID35673349
PMCPMC9167570

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.